MSPAF yields 33.78% · JNJ yields 2.13%● Live data
📍 MSPAF pulled ahead of the other in Year 1
Combined, MSPAF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MSPAF + JNJ for your $10,000?
Growens S.p.A., together with its subsidiaries, engages in the cloud marketing technology business in Italy, other European countries, the Americas, and Asia. It operates through E-mail Marketing, Mobile Marketing/Messaging, and Marketing Automation Segments. The company is involved in the development and sale of technologies for the mass sending of e-mails and mobile messaging through the SMS channel for marketing and transaction purposes. It also provides e-mail and newsletter editing tools; marketing technology solutions; and professional consulting services. In addition, the company offers MailUp, a platform that offers data presentation tools, including statistics for engagement that presents statistical data to help users enhance the effectiveness of their campaigns through e-mail and then to take corrective actions to enhance the performance of future campaigns, as well as the multi-list dashboard feature, which is a summary tool to have an immediate overview of the progress of campaigns. Further, it provides BEE, a drag-and-drop editor for e-mails and landing pages; Acumbamail, a Spanish e-mail marketing platform, which allows the creation, sending, and management of multi-channel marketing campaign; and Datatrics platform, which allows the marketing teams to build experiences based on data managed by artificial intelligence. The company was formerly known as Mailup S.p.A. and changed its name to Growens S.p.A. in April 2021. Growens S.p.A. was founded in 2002 and is headquartered in Milan, Italy.
Full MSPAF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.